The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2024

Filed:

Oct. 16, 2014
Applicant:

The General Hospital Corporation, Boston, MA (US);

Inventor:

Denise L. Faustman, Boston, MA (US);

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/566 (2006.01); A61K 39/04 (2006.01); A61K 45/06 (2006.01); G01N 33/50 (2006.01); G01N 33/564 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/566 (2013.01); A61K 39/04 (2013.01); A61K 45/06 (2013.01); G01N 33/505 (2013.01); G01N 33/564 (2013.01); A61K 2039/572 (2013.01); G01N 2333/47 (2013.01); G01N 2333/62 (2013.01); G01N 2333/70517 (2013.01); G01N 2800/042 (2013.01); G01N 2800/24 (2013.01); G01N 2800/52 (2013.01);
Abstract

The invention features methods of identifying a subject having an autoimmune disease, such as type 1 diabetes, as likely to respond to treatment with a tumor necrosis factor-α (TNF-α) receptor II activator. The method involves measuring CD8 protein density on the surface of autoreactive CD8T cells and identifying the subject as likely to respond to the treatment if the CD8 protein density is reduced relative to a reference CD8T cell. For type 1 diabetes, the method may involve measuring C-peptide levels in an in vitro biological sample from the subject, identifying the subject as likely to respond to the treatment if the C-peptide levels are detectable, and identifying the subject as unlikely to respond to the treatment if the C-peptide are substantially undetectable. The invention also features pharmaceutical compositions of one or more TNFR2 activators for use in treating an autoimmune disease in a subject identified as likely to respond to the treatment prior to the treating by according to the methods of the invention.


Find Patent Forward Citations

Loading…